{"product_id":"clinical-dilemmas-in-viral-liver-disease-isbn-9781119533399","title":"Clinical Dilemmas in Viral Liver Disease","description":"\u003cp\u003e\u003cb\u003eThe only evidence-based book to approach viral liver disease by focusing exclusively on the clinical dilemmas encountered by hepatologists and their medical teams\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAlthough viral hepatitis is a growing public health risk around the world, the World Health Organization (WHO) views the elimination of hepatitis infection over the next several as an achievable goal. Effective pharmaceutical therapies are now available, yet medical teams caring for patients with viral hepatitis are challenged when looking for answers to specific questions in the current medical literature. The second edition of \u003ci\u003eClinical Dilemmas in Viral Liver Disease \u003c\/i\u003eprovides evidence-based guidance for medical teams involved in diagnosing, treating, and managing patients with viral liver disease.\u003c\/p\u003e \u003cp\u003eThis fully updated book explores developments in new treatments and new diagnostic approaches that are contributing to WHO goals of viral elimination. Brief, easily referenced chapters examine clearly defined topics, addressing the clinical questions and difficulties encountered by medical teams in day-to-day practice. Contributions by an international team of investigators and clinicians address clinical questions and issues which are seldom found in standard textbooks and online repositories. Offering practical guidance on the specific challenges and dilemmas of treating viral liver disease, this unique volume: \u003c\/p\u003e \u003cul\u003e \u003cli\u003eProvides practical, evidence-based guidance on topical and controversial issues\u003c\/li\u003e \u003cli\u003eAddresses understudied questions that arise in day-to-day clinical practice\u003c\/li\u003e \u003cli\u003eDiscusses the challenges surrounding global elimination programs\u003c\/li\u003e \u003cli\u003ePresents focused approach that is supported by current literature and expert opinion\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThe second edition of\u003ci\u003e Clinical Dilemmas in Viral Liver Disease \u003c\/i\u003eis required reading for practicing and trainee hepatologists, gastroenterologists, transplant surgeons, virologists, and other practitioners involved in caring for patients with liver disease.\u003c\/p\u003eDas einzige evidenzbasierte Fachbuch zu viralen Lebererkrankungen, das sich ausschließlich mit schwierigen Situationen beschäftigt, mit denen sich klinische Hepatologen und das medizinische Personal immer wieder auseinandersetzen müssen.\u003cbr\u003e \u003cbr\u003e Auch wenn die virale Hepatitis weltweit auf dem Vormarsch ist und eine wachsende Bedrohung im Gesundheitswesen darstellt, ist für die Weltgesundheitsorganisation (WHO) die Ausrottung von Hepatitisinfektionen mittelfristig ein erreichbares Ziel. Wirksame Medikamente und Therapien stehen zwar zur Verfügung, das medizinische Personal, das Patienten mit viraler Hepatitis betreut, steht aber immer wieder vor der Herausforderung, in der heutigen medizinischen Literatur Antworten auf spezifische Fragen zu finden. Die 2. Auflage von Clinical Dilemmas in Viral Liver Disease ist ein evidenzbasierter Leitfaden für medizinisches Personal in den Bereichen Diagnose, Behandlung und Management von Patienten mit viralen Lebererkrankungen.\u003cbr\u003e \u003cbr\u003e Das komplett überarbeitete Referenzwerk zeigt neue Behandlungs- und Diagnoseansätze, die beitragen, die WHO-Ziele zu erreichen. Die einzelnen Kapitel untersuchen klar umrissene Themenfelder, gehen auf klinische Fragestellungen und Schwierigkeiten ein, vor denen Mediziner tagtäglich stehen. International renommierte Forscher und Kliniker beschäftigen sich in ihren Beiträgen mit klinischen Fragen und Problemen, die anderen Standardwerken und Online-Datensammlungen vielfach unberücksichtigt bleiben. Dieses einzigartige Fachbuch bietet praktische Hilfestellung zu den spezifischen Herausforderungen und Kernfragen bei der Behandlung von Patienten mit viralen Lebererkrankungen:\u003cbr\u003e - Bietet praxisorientierte, evidenzbasierte Hilfestellung zu aktuellen und kontroversen Themen.\u003cbr\u003e - Beschäftigt sich mit Fragestellungen, die im Klinikalltag auftreten und bislang wenig untersucht wurden.\u003cbr\u003e - Erörtert die Herausforderungen rund um globale Programme zur Ausrottung von Hepatitisinfektionen.\u003cbr\u003e - Folgt einem zielgerichteten Ansatz und greift dabei auf aktuelle Literatur und Expertenmeinungen zurück.\u003cbr\u003e \u003cbr\u003e Die 2. Auflage von Clinical Dilemmas in Viral Liver Disease ist ein Muss für Hepatologen, Gastroenterologen, Transplantationschirurgen, Virologen und medizinisches Fachpersonal, das Patienten mit Lebererkrankungen betreut.\u003cbr\u003e \u003cp\u003eList of Contributors vii\u003c\/p\u003e \u003cp\u003ePreface xi\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I: Investigating the Liver\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Noninvasive markers of fibrosis: how reliable are they? 3\u003cbr\u003e\u003ci\u003eLaurent Castera\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Liver biopsy in chronic viral hepatitis: is there still life left in it? 9\u003cbr\u003e\u003ci\u003eJaspreet Suri and Michael P. Curry\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Screening for hepatocellular carcinoma in viral liver disease: any new biomarkers on the horizon? 15\u003cbr\u003e\u003ci\u003eSaroja Bangaru, Jorge A. Marrero, and Amit G. Singal\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Realistic estimates of hepatitis C virus and hepatitis B virus disease burden 19\u003cbr\u003e\u003ci\u003eHomie Razavi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II: Today’s Therapies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eSection 1: HCV\u003c\/p\u003e \u003cp\u003e5 Acute hepatitis C: treat immediately or give a chance to spontaneously clear? 29\u003cbr\u003e\u003ci\u003eDavid E. Kaplan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Is ribavirin alive or dead in the current era of HCV therapy? 35\u003cbr\u003e\u003ci\u003eVijay Prabhakar and Paul Y. Kwo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Hepatitis C virus genotype and viral testing, and on‐treatment monitoring: necessary or overkill? 41\u003cbr\u003e\u003ci\u003eSirina Ekpanyapong and K. Rajender Reddy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Treatment of hepatitis C virus in renal disease: can we use all the drugs without additional monitoring? 48\u003cbr\u003e\u003ci\u003eStanislas Pol\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Does directly acting antiviral therapy improve quality of life? 54\u003cbr\u003e\u003ci\u003eDaniel M. Forton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Morbid obesity and hepatitis C: treat as normal or are there additional issues to consider? 59\u003cbr\u003e\u003ci\u003eMaría Fernanda Guerra, Javier Ampuero, and Manuel Romero‐Gómez\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Generic direct‐acting antiviral agents: do they work well? 66\u003cbr\u003e\u003ci\u003eOmar Salim Al Siyabi and Seng‐Gee Lim\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Impact and management of patients with multiple hepatitis C virus genotypes 74\u003cbr\u003e\u003ci\u003ePeter Ferenci\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Hepatitis C virus and injecting drug use: what are the challenges? 78\u003cbr\u003e\u003ci\u003eOlav Dalgard\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Hepatitis B virus reactivation while on hepatitis C virus direct‐acting antiviral therapy: is that a real concern and when is it a concern? 82\u003cbr\u003e\u003ci\u003eMarina Serper\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Drug–drug interactions with direct‐acting antivirals: when do we need to care? 86\u003cbr\u003e\u003ci\u003eFiona Marra and David Back\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Treatment of hepatitis C in children 94\u003cbr\u003e\u003ci\u003eMaureen M. Jonas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 While direct‐acting antivirals are effective, are there any unique safety considerations? 97\u003cbr\u003e\u003ci\u003eOlivia Pietri, Félix Trottier‐Tellier, and Marc Bourlière\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Harm reduction strategies to prevent new infections and reinfections among people who inject drugs: how effective are they? 106\u003cbr\u003e\u003ci\u003eJason Grebely and Marianne Martinello\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Hepatitis C virus therapy in advanced liver disease: treat or transplant and treat? 112\u003cbr\u003e\u003ci\u003eChalermrat Bunchorntavakul and K. Rajender Reddy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Hepatocellular carcinoma and hepatitis C virus: which should be treated first? 117\u003cbr\u003e\u003ci\u003eMario U. Mondelli, Andrea Lombardi, and Massimo Colombo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Should we incentivize patients to take hepatitis C virus therapy? 122\u003cbr\u003e\u003ci\u003eEd Gane\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Treating prisoners with hepatitis C: should we do it and how? 125\u003cbr\u003e\u003ci\u003eSeth Francis‐Graham and William Rosenberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Use of hepatitis C virus‐positive organs for uninfected recipients in the era of effective and safe direct‐acting antivirals: pros and cons 132\u003cbr\u003e\u003ci\u003eSirina Ekpanyapong and K. Rajender Reddy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Is real‐life hepatitis C virus therapy as effective as in clinical trials? 138\u003cbr\u003e\u003ci\u003eJessica Su and Joseph K. Lim\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eSection 2: HBV, HDV, and HEV\u003c\/p\u003e \u003cp\u003e25 Management of acute hepatitis B infection: when should we offer antiviral therapy? 145\u003cbr\u003e\u003ci\u003eEmma Hathorn and David J. Mutimer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Rethinking the inactive carrier state: management of patients with low‐replicative HBeAg‐negative chronic hepatitis B and normal liver enzymes 150\u003cbr\u003e\u003ci\u003eMaría Buti, Mar Riveiro‐Barciela, and Rafael Esteban\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Hepatitis B e antigen‐positive chronic hepatitis B infection with minimal changes on liver biopsy: what to do next 156\u003cbr\u003e\u003ci\u003eApostolos Koffas and Patrick T. Kennedy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 The management of hepatitis B virus in pregnancy 160\u003cbr\u003e\u003ci\u003eHenry L.Y. Chan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Treatment of hepatitis B in children 164\u003cbr\u003e\u003ci\u003eMaureen M. Jonas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Hepatitis B vaccine failures: how do we handle them? 169\u003cbr\u003e\u003ci\u003eDaniel Shouval\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 The stopping rules in hepatitis B virus therapy: can we provide any guidance? 175\u003cbr\u003e\u003ci\u003eFlorian van Bömmel and Thomas Berg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 Hepatitis C and hepatitis B coinfection 182\u003cbr\u003e\u003ci\u003eChun‐Jen Liu and Jia‐Horng Kao\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Chronic hepatitis E virus infection: is it reality or hype and where does it matter? 189\u003cbr\u003e\u003ci\u003eNassim Kamar and Jacques Izopet\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Hepatitis E virus vaccines: have they arrived – when, where and for whom? 193\u003cbr\u003e\u003ci\u003eAmit Goel and Rakesh Aggarwal\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III: Clinical Set‐up and the Future\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e35 Do we need expert hepatitis C virus treaters or are amateur treaters good enough? 203\u003cbr\u003e\u003ci\u003eShyamasundaran Kottilil and Poonam Mathur\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 Hepatitis C vaccines: how close are we to the promised land? 208\u003cbr\u003e\u003ci\u003eTimothy Donnison, Senthil Chinnakannan, Paola Cicconi, and Eleanor Barnes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e37 Elimination of hepatitis C virus in high‐prevalence, low‐income countries: is it feasible? 216\u003cbr\u003e\u003ci\u003eMahmoud Abdo and Hadeel Gamal Eldeen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e38 Hepatitis B virus diagnostics: anything new? 220\u003cbr\u003e\u003ci\u003eDina Ginzberg, Robert J. Wong, and Robert G. Gish\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IV: Ongoing Controversies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e39 Is hepatocellular carcinoma risk impacted favorably or unfavorably by hepatitis C virus therapy with direct‐acting antivirals? 233\u003cbr\u003e\u003ci\u003eGiuseppe Cabibbo, Calogero Cammà, and Antonio Craxì\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e40 Global elimination of hepatitis C virus by 2030: the optimistic view 238\u003cbr\u003e\u003ci\u003eGregory J. Dore and Marianne Martinello\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e41 Global elimination of hepatitis C virus by 2030: the pessimistic view 244\u003cbr\u003e\u003ci\u003eThomas G. Cotter and Michael Charlton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 250\u003c\/p\u003e  \u003cp\u003eEdited by \u003c\/p\u003e\u003cp\u003e\u003cb\u003eGraham R. Foster PhD, FRCP,\u003c\/b\u003e Professor of Hepatology, The Blizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eK. Rajender Reddy MD, FACP, FACG, FRCP, FAASLD,\u003c\/b\u003e Ruimy Family President's Distinguished Professor of Medicine, Professor of Medicine in Surgery, Director of Hepatology, Director of Viral Hepatitis Center, Medical Director of Liver Transplantation, University of Pennsylvania, Philadelphia, PA, USA.   \u003c\/p\u003e\u003cp\u003e\u003cb\u003eClinical Dilemmas in Viral Liver Disease\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003e\u003cb\u003eThe only evidence-based book to approach viral liver disease by focusing exclusively on the clinical dilemmas encountered by hepatologists and their medical teams\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eAlthough viral hepatitis is a growing public health risk around the world, the World Health Organization (WHO) views the elimination of hepatitis infection over the next several years as an achievable goal. Effective pharmaceutical therapies are now available, yet medical teams caring for patients with viral hepatitis are challenged when looking for answers to specific questions in the current medical literature. The second edition of \u003ci\u003eClinical Dilemmas in Viral Liver Disease\u003c\/i\u003e provides evidence-based guidance for medical teams involved in diagnosing, treating, and managing patients with viral liver disease. \u003c\/p\u003e\u003cp\u003eThis fully updated book explores developments in new treatments and new diagnostic approaches that are contributing to WHO goals of viral elimination. Brief, easily referenced chapters examine clearly defined topics, addressing the clinical questions and difficulties encountered by medical teams in day-to-day practice. Contributions by an international team of investigators and clinicians address clinical questions and issues which are seldom found in standard textbooks and online repositories. Offering practical guidance on the specific challenges and dilemmas of treating viral liver disease, this unique volume: \u003c\/p\u003e\u003cul\u003e \u003cli\u003eProvides practical, evidence-based guidance on topical and controversial issues\u003c\/li\u003e \u003cli\u003eAddresses understudied questions that arise in day-to-day clinical practice\u003c\/li\u003e \u003cli\u003eDiscusses the challenges surrounding global elimination programs\u003c\/li\u003e \u003cli\u003ePresents focused approach that is supported by current literature and expert opinion\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThe second edition of \u003ci\u003eClinical Dilemmas in Viral Liver Disease\u003c\/i\u003e is required reading for practicing and trainee hepatologists, gastroenterologists, transplant surgeons, virologists, and other practitioners involved in caring for patients with liver disease.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47988932182245,"sku":"NP9781119533399","price":102.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119533399.jpg?v=1761782104","url":"https:\/\/k12savings.com\/products\/clinical-dilemmas-in-viral-liver-disease-isbn-9781119533399","provider":"K12savings","version":"1.0","type":"link"}